Department of Hepatobiliary and Pancreatic Surgery, University Hospitals of Leicester NHS Trust, Gwendolen Road, Leicester, LE5 4PW, UK.
Discipline of Surgery, The University of Adelaide, The Queen Elizabeth Hospital, Adelaide, South Australia, Australia.
Langenbecks Arch Surg. 2021 May;406(3):537-545. doi: 10.1007/s00423-020-02049-w. Epub 2021 Jan 3.
The clinical significance of indeterminate pulmonary nodules (IPN) in patients with resectable pancreatic adenocarcinoma (PDAC) is unknown. The rate of detection on IPN has risen due to enhanced staging investigations to determine resectability. IPNs detected on preoperative imaging represent a clinical dilemma and complicate decision-making. Currently, there are no recommendations on the management of IPN. This review provides a comprehensive overview of the current knowledge on the natural history of IPN detected among patients with resectable PDAC.
A systematic review based on a search in Medline and Embase databases was performed. All clinical studies evaluating the significance of IPN in patients with resectable PDAC were included. PRISMA guidelines were followed.
Five studies met the inclusion criteria. The total patient population was 761. The prevalence of IPN reported ranged from 18 to 71%. The median follow-up duration was 17 months. The median overall survival was 19 months. Patients with pre-operative IPN which subsequently progressed to clinically recognizable pulmonary metastases, ranged from 1.5 to 16%. Four studies found that there was no significant difference in median overall survival in patients with or without IPNs.
This is a first review on the significance of IPN in patients with resectable PDAC. The preoperative presence of IPN does not demonstrate an association with overall survival after surgery. The identification of IPN is a significant finding however it should not preclude patients with resectable PDAC from undergoing curative resection.
可切除胰腺腺癌(PDAC)患者中未定性肺结节(IPN)的临床意义尚不清楚。由于增强分期检查以确定可切除性,IPN 的检出率有所上升。术前影像学检测到的 IPN 代表了临床困境,使决策复杂化。目前,尚无关于 IPN 管理的建议。本综述提供了对可切除 PDAC 患者中检测到的 IPN 自然史的当前知识的全面概述。
基于对 Medline 和 Embase 数据库的搜索进行了系统评价。纳入了所有评估可切除 PDAC 患者中 IPN 意义的临床研究。遵循 PRISMA 指南。
符合纳入标准的研究有 5 项。总患者人群为 761 人。报告的 IPN 患病率范围为 18%至 71%。中位随访时间为 17 个月。中位总生存期为 19 个月。术前存在 IPN 且随后进展为临床可识别的肺转移的患者比例为 1.5%至 16%。四项研究发现,有无 IPN 的患者的中位总生存期无显著差异。
这是首次对可切除 PDAC 患者中 IPN 意义的综述。术前存在 IPN 与手术后的总体生存率无关联。虽然识别出 IPN 是一个重要的发现,但它不应阻止可切除 PDAC 患者接受根治性切除。